Abstract 1011P
Background
Portal vein tumor thrombus (PVTT) has a high incidence and poor prognosis in hepatocellular carcinoma (HCC) patients, and the treatment demand for such patients is currently unmet. This study aimed to evaluate efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and sintilimab in HCC with PVTT.
Methods
In this prospective study, eligible participants were enrolled and randomized (1:1) into TACE combined with lenvatinib and sintilimab (TACE-LEN-SIN) group and TACE combined with lenvatinib (TACE-LEN) group. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included overall survival (OS), objective response rate (ORR) and disease control rate (DCR) according to mRECIST, and safety.
Results
116 patients were enrolled from January 2022 to December 2022, 58 patients in each group. Patients had a median age of 50 (range, 51-64.2) years and mostly were male (80.2%). Hepatitis B virus infection was the main cause of HCC (85.3%). 37 (31.9%) patients had extrahepatic metastases. As of April 2023, 49 (84.5%) patients in the TACE-LEN group had disease progression and 38 (65.5%) died, while 37 (63.8%) patients in the TACE-LEN-SIN group had disease progression and 16 (27.6%) died. Both median PFS (4.17 vs. 3.33 months, P = 0.01) and median OS (not reached (NR) vs. 8.53 months, P = 0.003) in the TACE-LEN-SIN group were significantly longer than those in the TACE-LEN group. ORR (22.4% vs. 12.1%, P = 0.219) and DCR (69.0% vs. 53.4%, P = 0.127) were slightly higher in the triple group than in the dual group. The results of multivariate Cox regression also found that TACE-LEN-SIN treatment was an independent protective factor for PFS (HR: 0.62, 95% CI: 0.40 – 0.95, P = 0.028) and OS (HR: 0.45, 95% CI: 0.25 – 0.82, P = 0.008). The most common adverse events (AEs) were hypertension, diarrhea and fatigue. And no significant differences in the incidence of AEs between the two groups, except for those related to Sintilimab.
Conclusions
TACE combined with lenvatinib and sintilimab improved survival outcomes without increasing the unpredictable safety profile compared with TACE combined with lenvatinib for HCC with PVTT.
Clinical trial identification
ChiCTR2200066830.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18